Changes in Quality-of-Life and Psychosocial Adjustment among Multiple Myeloma Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1, 2009, Pages 12-20

  Sherman, Allen C ^a   Simonton, Stephanie ^a   Latif, Umaira ^c   Plante, Thomas G ^d   Anaissie, Elias J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c METHODIST DALLAS MEDICAL CENTER   (United States)

^d SANTA CLARA UNIVERSITY   (United States)

Author keywords

Hematopoietic stem cell transplantation; Multiple myeloma; Psychosocial adjustment; Quality of life

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANXIETY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRIEF SYMPTOM INVENTORY; CLINICAL TRIAL; DEPRESSION; DISTRESS SYNDROME; DRUG MEGADOSE; EARLY DIAGNOSIS; EARLY INTERVENTION; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GRAFT VERSUS HOST REACTION; HUMAN; IMPACT OF EVENTS SCALE; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; PAIN; PSYCHOSOCIAL CARE; QUALITY OF LIFE; SCORING SYSTEM; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE; WELLBEING;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGE FACTORS; AGED; DEPRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PAIN; QUALITY OF LIFE; SOCIAL ADJUSTMENT; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 58149197558     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.09.023     Document Type: Article

References (36)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
2. Child J., Morgan G., Davies F., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
3. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
4. Jenal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2007 57 (2007) 43-66
5. Gulbrandsen N., Wisloff F., Brinch L., et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 18 (2001) 65-77
6. Gulbrandsen N., Wisloff F., Nord E., et al. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 66 (2001) 328-336
7. Gulbrandsen N., Hjermstad M.J., and Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of clinical importance of score differences. Eur J Haematol 72 (2004) 172-180
8. Badros A., Barlogie B., Siegel E., et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114 (2001) 1-9
9. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
10. Sherman A.C., Coleman E.A., Griffith K., et al. Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation. Support Care Cancer 11 (2003) 568-574
11. Sherman A.C., Simonton S., Latif U., et al. Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant 33 (2004) 955-962
12. Campagnaro E., Saliba R., Giralt S., et al. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 112 (2008) 1617-1624
13. Anderson K.O., Giralt S.A., Mendoza T.R., et al. Symptom burden in patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 39 (2007) 759-766
14. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 (2006) 1021-1030
15. Choon-Kee L., Barlogie B., Munshi N., et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21 (2003) 2732-3739
16. McQuellon R.P., Russell G.B., Cella D.F., et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 19 (1997) 357-368
17. Holzner B., Kemmler G., Cella D., et al. Normative data for functional assessment of cancer therapy. Acta Oncol 43 (2004) 153-160
18. Derogatis L.R. Brief Symptom Inventory: Administration, Scoring, and Procedures Manual (1993), National Computer Systems, Inc, Minneapolis, MN
19. Horowitz M.J., Wilner N., and Alvarez W. Impact of Events Scale: a measure of subjective stress. Psychosom Med 41 (1979) 209-218
20. Diener E., Emmons R., Larsen R., et al. The Satisfaction with Life scale. J Pers Soc Psychol 47 (1985) 1105-1117
21. Courneya K.S., Keats M.R., and Turner A.R. Physical exercise and quality of life in cancer patients following high-dose chemotherapy and autologous bone marrow transplantation. Psychooncology 9 (2000) 127-136
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences (1977), Academic Press, New York
23. Brucker P.S., Yost K., Cashy J., et al. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General. Eval Health Prof 28 (2005) 195-211
24. Fife B.L., Huster G.A., Cornetta K.G., et al. Longitudinal study of adaptation to the stress of bone marrow transplantation. J Clin Oncol 18 (2000) 1539-1549
25. Andrykowski M.A., Bishop M.M., Hahn E.A., et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 23 (2005) 599-608
26. Uyl-de-Groot C.A., Buijt I., Gloudemans I.J.M., et al. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 74 (2005) 136-143
27. Schulmeister L., Quiett K., and Mayer K. Quality of life, quality of care, and patient satisfaction: perceptions of patients undergoing outpatient autologous stem cell transplantation. Oncol Nurs Forum 32 (2005) 57-67
28. Gaston-Johansson F., and Foxall M. Psychological correlates of quality of life across the autologous bone marrow transplant experience. Cancer Nurs 19 (1996) 170-176
29. Zittoun R., Achard S., and Ruszniewski M. Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psychooncology 8 (1999) 64-73
30. Larsen J., Nordstrom G., Bjorkstrand B., et al. Symptom distress, functional status, and health-related quality of life before high-dose chemotherapy with stem-cell transplantation. Eur J Cancer Care 12 (2003) 71-80
31. Holland J. NCCN practice guidelines for the management of psychosocial distress. Oncology 13 (1999) 113-147
32. Atkinson A., Barsevick A., Cella D., et al. NCCN practice guidelines for cancer-related fatigue. Oncology 14 (2000) 151-161
33. Ransom S., and Jacobsen P.B. Validation of the distress thermometer with bone marrow transplant patients. Psychooncology 15 (2006) 604-612
34. Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 38 (2006) 715-720
35. Baker F., Denniston M., Smith T., et al. Adult cancer survivors: how are they faring?. Cancer 104 (2005) 2565-2576
36. Sherman AC, Plante TP, Simonton S, et al. Prospective study of religious coping among patients undergoing autologous stem cell transplantation. Journal of Behavioral Medicine, in press.